Journal of Clinical Endocrinology & Metabolism, Vol 80, 3601-3607, Copyright © 1995 by Endocrine Society

ARTICLES

Sandostatin LAR in acromegalic patients: a dose-range study

AK Flogstad, J Halse, T Haldorsen, I Lancranjan, P Marbach, C Bruns and J Jervell
Medical Department B, Rikshospitalet, Oslo, Norway.

Sandostatin LAR is a sustained release formulation of octreotide that has been developed by microencapsulating the drug with biodegradable poly(lactide-glycolide)-glucose. We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4- week pretreatment period with octreotide given sc. Two double blind studies were performed. Initially, 14 patients were randomized and observed over 42 days after a single im injection of 3, 6, 9, or 12 mg Sandostatin LAR. In the second study, 15 patients were randomized and observed over 60 days after a single im injection of either 20 or 30 mg Sandostatin LAR. Assessments of 12-h GH and octreotide profiles and adverse events were made on day -14 (during treatment with Sandostatin, sc); day 0 (off treatment after wash-out period); days 1, 7, 14, 21, 28, 35, and 42; and, for study 2, also on days 49 and 60 after the im injection. Only injections of 20 or 30 mg were followed by a suppression of basal GH and insulin-like growth factor I to levels comparable to those seen during sc treatment. The suppression of mean GH to less than 5 micrograms/L lasted for 4 weeks in the group receiving 20 mg and for at least 6 weeks in those given 30 mg Sandostatin LAR. The pharmacokinetic profile fitted a biphasic drug release model previously described for peptides in similar drug delivery systems. Serum concentrations correlated with the im administered dose. Suppression of GH and insulin-like growth factor I was achieved at serum octreotide concentrations exceeding approximately 600 ng/L. Tolerability was good. Sandostatin LAR holds promise as a valuable drug for the treatment of acromegaly. The results of ongoing long term studies will provide further necessary knowledge of the drug.

This article has been cited by other articles:

				L. Nachtigall, A. Delgado, B. Swearingen, H. Lee, R. Zerikly, and A. Klibanski Changing Patterns in Diagnosis and Therapy of Acromegaly over Two Decades J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2035 - 2041. [Abstract] [Full Text] [PDF]

				S.-C. Hua, Y.-H. Yan, and T.-C. Chang Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly Eur. J. Endocrinol., December 1, 2006; 155(6): 831 - 837. [Abstract] [Full Text] [PDF]

				D Paran, J Bernheim, I Golan, D Caspi, J Bernheim, and S Benchetrit Somatostatin Treatment Attenuates Proteinuria and Prevents Weight Loss in NZB/W F1 Mice Lupus, August 1, 2006; 15(8): 526 - 531. [Abstract] [PDF]

				G M Besser, P Burman, and A F Daly Predictors and rates of treatment-resistant tumor growth in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193. [Abstract] [Full Text] [PDF]

				A. Saveanu, E. Lavaque, G. Gunz, A. Barlier, S. Kim, J. E. Taylor, M. D. Culler, A. Enjalbert, and P. Jaquet Demonstration of Enhanced Potency of a Chimeric Somatostatin-Dopamine Molecule, BIM-23A387, in Suppressing Growth Hormone and Prolactin Secretion from Human Pituitary Somatotroph Adenoma Cells J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5545 - 5552. [Abstract] [Full Text] [PDF]

				D Paran, O Elkayam, A Mayo, H Paran, M Amit, M Yaron, and D Caspi A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis Ann Rheum Dis, September 1, 2001; 60(9): 888 - 891. [Abstract] [Full Text] [PDF]

				A. Colao, D. Ferone, P. Marzullo, P. Cappabianca, S. Cirillo, V. Boerlin, I. Lancranjan, and G. Lombardi Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2779 - 2786. [Abstract] [Full Text] [PDF]

				S. Melmed, I. Jackson, D. Kleinberg, and A. Klibanski Current Treatment Guidelines for Acromegaly J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2646 - 2652. [Abstract] [Full Text]

				A. J. van der Lely and W. W. de Herder The Role of Radiotherapy in Acromegaly J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3185 - 3186. [Full Text] [PDF]

				A. K. Flogstad, J. Halse, S. Bakke, I. Lancranjan, P. Marbach, Ch. Bruns, and J. Jervell Sandostatin LAR in Acromegalic Patients: Long Term Treatment J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 23 - 28. [Abstract] [Full Text] [PDF]